Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to follow Alaunos Therapeutics’ next breakthrough is tough when its SEC disclosures run hundreds of pages of scientific jargon and accounting rules. Whether you’re watching cash runway for TCR-T trials or scanning for FDA milestone updates, the detail is buried deep in 10-K footnotes and sudden 8-K releases.
Stock Titan surfaces the answers in seconds. Our AI-powered summaries turn Alaunos Therapeutics SEC filings explained simply into reality—highlighting pipeline progress, licensing agreements and material risks. Need the latest Alaunos Therapeutics quarterly earnings report 10-Q filing? It’s here with plain-English context and side-by-side metrics. Curious about Alaunos Therapeutics insider trading Form 4 transactions? Real-time alerts track every executive move, so you can spot buying or selling before the market reacts.
Explore every disclosure type in one place:
- Alaunos Therapeutics annual report 10-K simplified – understand R&D spend, patent portfolios and future funding needs.
- Instant analysis of Alaunos Therapeutics 8-K material events explained – from clinical data releases to financing deals.
- Alaunos Therapeutics proxy statement executive compensation – see how leadership is incentivized to advance the TCR-T platform.
- Alaunos Therapeutics earnings report filing analysis – dive into quarter-over-quarter trial costs and milestones.
- Alaunos Therapeutics Form 4 insider transactions real-time – monitor executive stock transactions without scrolling through EDGAR.
Stop sifting through dense biotech language. By understanding Alaunos Therapeutics SEC documents with AI, you’ll quickly gauge clinical momentum, funding strength and insider confidence—all the data you need to make informed decisions.
Ferdinand Groenewald, identified as Vice President of Finance at Alaunos Therapeutics, Inc. (TCRT), reported transactions dated 08/18/2025. He acquired 10,775 shares of common stock and was granted an employee stock option for 4,000 shares with an exercise price of $2.32 and an expiration date of 08/17/2035. The option vests one-sixteenth of the underlying shares in equal quarterly installments beginning 11/18/2025, subject to continued service.
The Form 4 shows the shares and options are held directly after the transactions. The filing is signed by Mr. Groenewald on 08/20/2025. No additional compensation details or company valuation metrics are provided in this filing.
Holger Weis, Chief Executive Officer and Director of Alaunos Therapeutics, Inc. (TCRT), exercised employee stock options to acquire 13,676 shares on 08/18/2025. The exercised options carry a $2.32 per-share exercise price and are fully vested as of the transaction date, resulting in 13,676 shares beneficially owned by Mr. Weis following the transaction. The Form 4 was signed and dated 08/20/2025 by the reporting person. The filing shows an acquisition via option exercise rather than an open-market purchase and does not report any dispositions or other classes of securities.
Form 4 filing for Alaunos Therapeutics, Inc. (TCRT) discloses that director Robert W. Postma received new equity awards on July 3, 2025.
- Restricted stock units (RSUs): 4,050 shares of common stock granted at $0.00 cost and vested immediately, increasing his direct holding to 33,133 shares.
- Stock options: Option to purchase 6,400 shares at an exercise price of $5.00 per share, expiring July 3, 2035. One-twelfth of the option vests monthly starting July 3, 2025; any remaining unvested portion fully vests just before the 2026 annual meeting.
- Indirect holdings: 62,416 shares held through WaterMill Asset Management Corp. and 24 shares in a spouse’s IRA.
The transactions are incentive-based grants rather than market purchases or sales, so they do not immediately affect public float or cash flows. However, they modestly increase insider ownership and further align the director’s interests with shareholders.
Form 4 highlights: Director Jaime Vieser received new equity awards from Alaunos Therapeutics (TCRT) on 07/03/2025.
- Restricted Stock Units (RSUs): 3,400 common shares granted and fully vested immediately. This raised Vieser’s directly held stock from 17,759 to 21,159 shares.
- Employee Stock Options: 6,400 options with a $5.00 exercise price and 07/03/2035 expiry. One-twelfth vests each month; any unvested balance vests immediately before the 2026 annual meeting.
- Total beneficial ownership after the grant: 21,159 shares held directly, 2,100 shares held indirectly through children, and 13,503 shares held indirectly via Brushwood LLC where Vieser is Manager.
The awards were issued at $0.00 cost for the RSUs and standard option pricing for the options, indicating compensation rather than an open-market purchase. While the absolute numbers are modest relative to typical public-company share counts, the filing shows continued equity-based alignment between the director and shareholders.
FAQ
What is the current stock price of Alaunos Therapeutics (TCRT)?
What is the market cap of Alaunos Therapeutics (TCRT)?
